Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin [...]
Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin [...]
Through its investment in and collaboration with PsyLabs, the Company [...]